Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.41 |
| ▸ | PFKFB4 | Q16877 | 3/20 | 0.41 |
| ▸ | CMA1 | P23946 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | BCKDK | O14874 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845473 | 0.87 | MAPT (0.50) | MAPTALDH1A1CXCR2ROCK1NPSR1 | |
| SCHEMBL6958000 | 0.84 | MAPT (0.48) | MAPTCXCR2ROCK1NPSR1L3MBTL1 | |
| SCHEMBL121696 | 0.81 | MAPT (0.50) | MAPTALDH1A1ROCK1NPSR1L3MBTL1 | |
| SCHEMBL122587 | 0.81 | GPR35 (0.58) | MAPTROCK1NPSR1L3MBTL1PFKFB3 | |
| SCHEMBL121489 | 0.81 | MAPT (0.50) | MAPTCXCR2ROCK1NPSR1L3MBTL1 | |
| SCHEMBL7981541 | 0.81 | MAPT (0.45) | MAPTALDH1A1CXCR2ROCK1NPSR1 | |
| SCHEMBL3133584 | 0.79 | OGG1 (0.52) | MAPTMEN1ALDH1A1KMT2ACXCR2 | |
| SCHEMBL2099000 | 0.78 | HSD11B1 (0.61) | MAPTMEN1ALDH1A1KMT2AGSK3B | |
| SCHEMBL6659125 | 0.78 | MAPT (0.49) | MAPTMEN1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL3323953 | 0.78 | CXCR2 (0.47) | MAPTMEN1ALDH1A1KMT2ACXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1861384-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007117180-A1 | AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF | 'CHEMICAL DIVERSITY RESEARCH INSTITUTE' LTD. (RU) | 2007-10-18 | — | — | WO | disclosed |
| WO-2006100502-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
| US-6991902-B2 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1056732-B1 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMA (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CHONG WESLEY K M (US) | 2003-11-27 | — | — | US | disclosed |
| US-6569878-B1 | Such as 4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone for treating cancer | AGOURON PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| US-20030003505-A1 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| EP-1215208-A2 | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | Agouron Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| US-20020009748-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | ISIS PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| EP-1056732-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1999000669-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1998006671-A1 | METHODS FOR REMOVING UNREACTED ELECTROPHILES FROM A REACTION MIXTURE | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020009748-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | PNP, ATIC, DPYD | MAPT 4034/4885MEN1 971/4885ALDH1A1 1826/4885 |
| US-20030003505-A1 | Nucleobase heterocyclic combinatorialization | PNP, ATIC, DPYD | MAPT 4034/4885MEN1 971/4885ALDH1A1 1826/4885 |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | MAPT 4815/4885MEN1 3474/4885ALDH1A1 437/4885 |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CDK2, CDK4, CDK1 | MAPT 3466/4885MEN1 1999/4885ALDH1A1 1035/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | MAPT 4740/4885MEN1 2608/4885ALDH1A1 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.